JCB, Volume 17, Number 2, 2011 Editorial Vol.17 No. 2 (2011) Building biotechnology in Okinawa Yali Friedman Last fall I was invited to an international workshop with the aim of helping develop a research university in Okinawa, the Okinawa Institute of Science and Technology (OIST Commentary Vol.17 No. 2 (2011) Startup America: What it includes and opportunities for innovators David B Orange   Commentary Vol.17 No. 2 (2011) Singapore – Home base for expansion in Asia Kian-Teik Beh   Commentary Vol.17 No. 2 (2011) Traditional ecological knowledge: Impact on commercial health Mohammadali Khalvati   Article Vol.17 No. 2 (2011) The growing importance of incorporating US payers into biotechnology drug development decision-making Sarah Collins There are numerous biotechnology agents in the research and development (R&D) pipeline. In part because of the approximately 20 per cent annual increase in biotechn Article Vol.17 No. 2 (2011) Anticipating opportunities in industrial biotechnology: Sizing the market and growth scenarios Peter J Nieuwenhuizen Bio-based chemicals are being touted as the next big thing for the chemical industry and its customers. In particular they can offer significant opportunity for the che Article Vol.17 No. 2 (2011) Founding angels as early stage investment model to foster biotechnology start-ups Gunter Festel As a rule, in biotechnology and other technologies, a gap exists between innovations coming from academic research and the commercialisation of the results, which is a Article Vol.17 No. 2 (2011) The economic potential of plant-made pharmaceuticals in the manufacture of biologic pharmaceuticals James Kaufman Biologic pharmaceuticals have emerged to treat a number of diseases such as cancer and immune disorders. Although these drugs provide significant benefits, they have te From the Classroom Vol.17 No. 2 (2011) Developing graduate skills for the United Kingdom's commercial life science sector: Experiences from the ORBIS internship programme James Gazzard The United Kingdom's commercial life science sector is dependent on a pipeline of skilled professionals to retain a leading position in a globally competitive sector. W Legal and Regulatory Updates Vol.17 No. 2 (2011) EU Legal and Regulatory Update Gerry Kamstra   Legal and Regulatory Updates Vol.17 No. 2 (2011) Impact of recent IP caselaw on biomarkers and personalized medicine David A Gass   Legal and Regulatory Updates Vol.17 No. 2 (2011) Licensing issues in today's bankruptcy world Michael Schein   Legal and Regulatory Updates Vol.17 No. 2 (2011) Limitation of gene patents to functioning DNA Philip Webber   Book Review Vol.17 No. 2 (2011) Chronicling the development of myozyme: The Cure and Chasing Miracles Derek J Francis Geeta AnandThe Cure,HarperCollins Publishers Inc, New York, 2009, paperback, 368pp.,ISBN: 978-0060734404John F CrowleyChasing Miracles,Newmarket Book Review Vol.17 No. 2 (2011) Anatomy of a Patent Case Michael G Sullivan Anatomy of a patent caseGeorge F. Pappas – Editor-in-ChiefBNA Books, Arlington USA, 2009, paperback, 202pp., US $ 155.00,ISBN: 978-1570188572